Ignite Creation Date:
2025-12-25 @ 1:18 AM
Ignite Modification Date:
2026-06-29 @ 12:21 PM
Study NCT ID:
NCT07241793
Status:
RECRUITING
Last Update Posted:
2025-12-18
First Post:
2025-09-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Sponsor:
Sun Yat-sen University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2025-FXY-281
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None